Regulations.gov document
Reference 6 - Carter Practical considerations with 17-Hydroxyprogesterone caproate for…
Supporting & Related Material · FDA-2020-N-2029 · posted Oct 6, 2022
Key facts
| Document ID | FDA-2020-N-2029-0290 |
|---|---|
| Title | Reference 6 - Carter Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention RE Briefing Materials Supporting CDER’s Proposal to Withdraw Approval of Makena |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2020-N-2029 |
| Posted | Oct 6, 2022 |
At a glance
- 100–999 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: